EUCRISA (crisaborole)
Eucrisa is a topical ointment used for adults and children as young as three months old who have mild to moderate atopic dermatitis. It helps patients manage the symptoms of this skin condition through direct application to the affected areas. This medication provides a targeted approach for those dealing with persistent skin inflammation.
How EUCRISA Works
Eucrisa works by blocking the activity of an enzyme called phosphodiesterase 4 (PDE-4). This inhibition leads to higher levels of cyclic adenosine monophosphate (cAMP) within the cells. Although the precise way this process improves atopic dermatitis is not fully defined, it is the primary method by which the drug functions.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2016-12-14
- Patent Cliff
- 2030
- Routes
- TOPICAL
- Dosage Forms
- OINTMENT
EUCRISA Approval History
What EUCRISA Treats
1 indicationsEUCRISA is approved for 1 conditions since its original approval in 2016. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Atopic Dermatitis
EUCRISA Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
What's emerging in EUCRISA's indications
See all emerging drugs →Phase 3 candidates targeting molecules with no FDA-approved drug, in indications EUCRISA treats. First-in-class if their pivotal trials read out positive.
Drugs Similar to EUCRISA
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07352566 | 25-43621 | Ph 4 | not yet recruiting | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT03250663 | IRB00045841 | Ph 1 | completed | Eucrisa for Atopic Dermatitis |
| NCT03832010 results posted | IRB00178631 | Ph 4 | completed | Steroid-reducing Effects of Crisaborole |
| NCT05016284 | JW-100-RCT-001 | Ph 3 | withdrawn | Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis |
| NCT03645057 results posted | RSRB73062 | Ph 3 | completed | ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis |
| NCT04023084 | 2019-2879 | Ph 4 | completed | Response of Children With Atopic Dermatitis (Eczema) to Eucrisa |
| NCT03567980 results posted | 180306 | Ph 4 | completed | A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis |
| NCT03351114 results posted | Pro00086947 | Ph 2 | completed | Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
EUCRISA FDA Label Details
Indications & Usage
FDA Label (PDF)EUCRISA is indicated for the treatment of Atopic Dermatitis.
EUCRISA Patents & Exclusivity
Patents (8 active)
Exclusivity
Pro Intelligence Preview
Deep insights for EUCRISA
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2030
- • 8 active patents
Trial Analysis
- • 6 total trials
- • Stage: Mature
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment